SAN DIEGO, CA - March 12, 2025 ( NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY) today released the following note authored by its CEO, Jim Joyce.
After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback